All Stories

  1. Pharmacogenetics of alcohol use disorder treatments: an update
  2. Maintenance of drinking reductions are possible and associated with improvements in functioning.
  3. F123. Genome-Wide Epigenetic Signatures of Major Depressive Disorder in Women
  4. Predictors of Treatment Referral After AUDIT-C Screening for Heavy Drinking
  5. Examining the effects of alcohol on GABA A receptor mRNA expression and function in neural cultures generated from control and alcohol dependent donor induced pluripotent stem cells
  6. Collaborative phenotype inference from comorbid substance use disorders and genotypes
  7. Effects of Recent Alcohol Consumption Level on Neurocognitive Performance in HIV+ Individuals
  8. S100A10 identified in a genome-wide gene × cannabis dependence interaction analysis of risky sexual behaviours
  9. Correlates of Electronic Cigarettes Use Before and During Pregnancy
  10. Genomewide Association Study of Alcohol Dependence Identifies Risk Loci Altering Ethanol-Response Behaviors in Model Organisms
  11. Alcohol and nicotine codependence-associated DNA methylation changes in promoter regions of addiction-related genes
  12. Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats
  13. Examining FKBP5 mRNA expression in human iPSC-derived neural cells
  14. Genetic Factor Common To Schizophrenia And Hiv Infection Is Associated With Risky Sexual Behavior
  15. Urgency traits moderate daily relations between affect and drinking to intoxication among young adults
  16. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision
  17. Phenome-Wide Association Study for Alcohol and Nicotine Risk Alleles in 26394 Women
  18. Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks
  19. New Initiatives forAlcoholism: Clinical and Experimental Research
  20. Balancing Risk and Benefit in Heavy Drinkers Treated With Topiramate
  21. An Effective Method to Identify Heritable Components from Multivariate Phenotypes
  22. Smoking and Cellular Telephone Use Among Pregnant Women Seeking Prenatal Care
  23. Genome-wide association study of body mass index in subjects with alcohol dependence
  24. Refining multivariate disease phenotypes for high chip heritability
  25. Further analyses support the association between light eye color and alcohol dependence
  26. GABRA2Alcohol Dependence Risk Allele is Associated with Reduced Expression of Chromosome 4p12 GABAASubunit Genes in Human Neural Cultures
  27. Psychopharmacological Treatments for Substance Use Disorders
  28. Endorsement of the CONSORT Principles in Reporting Alcohol Clinical Trials inACER
  29. Eye color: A potential indicator of alcohol dependence risk in European Americans
  30. Genetic Vulnerability to Menthol Cigarette Preference in Women
  31. Which alcohol use disorder criteria contribute to the association ofADH1Bwith alcohol dependence?
  32. Genetics of Addiction
  33. Posttreatment Effects of Topiramate Treatment for Heavy Drinking
  34. Identifying heritable composite traits from multivariate phenotypes and genome-wide SNPs
  35. Genome-Wide Association Study of Copy Number Variations (CNVs) with Opioid Dependence
  36. What happens when people discontinue taking medications? Lessons from COMBINE
  37. ACER: Quo Vadis?
  38. Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol
  39. GRIK1 Genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink
  40. Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
  41. Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
  42. Multiview Comodeling to Improve Subtyping and Genetic Association of Complex Diseases
  43. Dutasteride reduces alcohol’s sedative effects in men in a human laboratory setting and reduces drinking in the natural environment
  44. Rate of progression from first use to dependence on cocaine or opioids: A cross-substance examination of associated demographic, psychiatric, and childhood risk factors
  45. The effects of aMAP2K5microRNA target site SNP on risk for anxiety and depressive disorders
  46. Multi-view singular value decomposition for disease subtyping and genetic associations
  47. Bilingual Semi-Structured Assessment for Drug Dependence and Alcoholism--English/Samoan Version
  48. Ttn as a likely causal gene for QTL of alcohol preference on mouse chromosome 2
  49. GRIK1 genotype and daily expectations of alcohol’s positive effects moderate the reduction of heavy drinking by topiramate.
  50. Multi-view biclustering for genotype-phenotype association studies of complex diseases
  51. An Interpersonal Model of Addiction Relapse
  52. Clinical Manual of Addiction Psychopharmacology
  53. Genome-wide Association Study Identifies New Susceptibility Loci for Posttraumatic Stress Disorder
  54. Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder
  55. Quadratic optimization to identify highly heritable quantitative traits from complex phenotypic features
  56. Deep resequencing of 17 glutamate system genes identifies rare variants inDISC1andGRIN2Baffecting risk of opioid dependence
  57. Pharmacological Treatments for Heavy Drinking
  58. Profiling of Childhood Adversity-Associated DNA Methylation Changes in Alcoholic Patients and Healthy Controls
  59. Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co-occurring alcohol and nicotine addiction?
  60. Insomnia in Alcohol Dependence: Predictors of Symptoms in a Sample of Veterans Referred from Primary Care
  61. Major Depression and PTSD in Pregnant Smokers Enrolled in Nicotine Gum Treatment Trial
  62. Ordered subset linkage analysis based on admixture proportion identifies new linkage evidence for alcohol dependence in African-Americans
  63. 5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity
  64. A multi-objective program for quantitative subtyping of clinically relevant phenotypes
  65. Improved methods to identify stable, highly heritable subtypes of opioid use and related behaviors
  66. Linkage Analysis Followed by Association Show NRG1 Associated with Cannabis Dependence in African Americans
  67. Identification of POMC Exonic Variants Associated with Substance Dependence and Body Mass Index
  68. Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence
  69. GABRA2 Genotype, Impulsivity, and Body Mass
  70. Personalized Treatment of Alcohol Dependence
  71. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment
  72. GABRA2 markers moderate the subjective effects of alcohol
  73. The 5-HTTLPR polymorphism moderates the effect of stressful life events on drinking behavior in college students of African descent
  74. Pilot Study of iPS-Derived Neural Cells to Examine Biologic Effects of Alcohol on Human Neurons In Vitro
  75. Association of COL25A1 with Comorbid Antisocial Personality Disorder and Substance Dependence
  76. Autosomal linkage scan for loci predisposing to comorbid dependence on multiple substances
  77. M3: an improved SNP calling algorithm for Illumina BeadArray data
  78. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women
  79. Post‐Treatment Outcomes in a Double‐Blind, Randomized Trial of Sertraline for Alcohol Dependence
  80. 5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder
  81. Comparison of Alcoholism Subtypes as Moderators of the Response to Sertraline Treatment
  82. A Genomewide Linkage Scan of Cocaine Dependence and Major Depressive Episode in Two Populations
  83. Agitated depression in substance dependence
  84. Empirically derived subtypes of opioid use and related behaviors
  85. Association of CHRNA4 polymorphisms with smoking behavior in two populations
  86. Variation in Genes Encoding the Neuroactive Steroid Synthetic Enzymes 5α-Reductase Type 1 and 3α-Reductase Type 2 Is Associated With Alcohol Dependence
  87. Variation in NGFB is associated with primary affective disorders in women
  88. How Should Addiction-Related Research at the National Institutes of Health be Reorganized?
  89. Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics
  90. Variation in the Nicotinic Acetylcholine Receptor Gene Cluster CHRNA5–CHRNA3–CHRNB4 and Its Interaction with Recent Tobacco Use Influence Cognitive Flexibility
  91. Placebo-Controlled Trial of Zonisamide for the Treatment of Alcohol Dependence
  92. In Reply
  93. A Prospective Cohort Study Investigating Factors Associated With Depression During Medical Internship
  94. Pharmacogenetics of Alcohol and Alcohol Dependence Treatment
  95. PMH13 CHARACTERISTICS AND COST OUTCOMES OF INSURED PATIENTS TREATED WITH EXTENDED-RELEASE NALTREXONE (XR-NTX) OR ORAL ALCOHOL DEPENDENCE MEDICATIONS
  96. Interaction of FKBP5 with Childhood Adversity on Risk for Post-Traumatic Stress Disorder
  97. Effects of Naltrexone Treatment for Alcohol-Related Disorders on Healthcare Costs in an Insured Population
  98. Analysis of extreme drinking in patients with alcohol dependence using Pareto regression
  99. Adolescent cannabis use increases risk for cocaine-induced paranoia
  100. A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated With Interferon-α Treatment
  101. Methamphetamine and Paranoia: The Methamphetamine Experience Questionnaire
  102. Confirmation and Generalization of an Alcohol-Dependence Locus on Chromosome 10q
  103. A genomewide ordered-subset linkage analysis for alcohol dependence in African-Americans
  104. Adverse childhood events as risk factors for substance dependence: Partial mediation by mood and anxiety disorders
  105. Functional polymorphisms in the serotonin 1B receptor gene (HTR1B) predict self‐reported anger and hostility among young men
  106. Subtypes of major depression in substance dependence
  107. Measurement of admixture proportions and description of admixture structure in different U.S. populations
  108. Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers
  109. Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers
  110. Targeted Naltrexone for Problem Drinkers
  111. Cognitive Flexibility is Associated with KIBRA Variant and Modulated by Recent Tobacco Use
  112. Genetics of alcohol dependence
  113. Sources of Unreliability in the Diagnosis of Substance Dependence
  114. Effect of Extended‐Release Naltrexone (XR‐NTX) on Quality of Life in Alcohol‐Dependent Patients
  115. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty
  116. Persistence with oral naltrexone for alcohol treatment: implications for health‐care utilization
  117. MultipleOPRgenes influence personality traits in substance dependent and healthy subjects in two American populations
  118. Nicotine Gum for Pregnant Smokers
  119. GENETIC STUDY: Tryptophan hydroxylase 2 gene and alcohol use among college students
  120. Effects of Prenatal Tobacco Exposure on Gene Expression Profiling in Umbilical Cord Tissue
  121. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
  122. Substance dependence low-density whole genome association study in two distinct American populations
  123. Topiramate as Treatment for Alcohol Dependence—Reply
  124. Acamprosate Efficacy in Alcohol‐Dependent Patients: Summary of Results from Three Pivotal Trials
  125. The validity of cocaine dependence subtypes
  126. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism
  127. ADH7 variation modulates extraversion and conscientiousness in substance-dependent subjects
  128. Letter to the Editor
  129. Genetics of Substance Dependence
  130. Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects
  131. CNR1 Variation Modulates Risk for Drug and Alcohol Dependence
  132. Memantine for Alcohol Dependence: An Open-label Pilot Study
  133. Brief motivational enhancement and coping skills interventions for heavy drinking
  134. Personality Traits of Agreeableness and Extraversion are Associated with ADH4 Variation
  135. Transdermal nicotine for smoking cessation in postmenopausal women
  136. Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions
  137. Genomewide Linkage Scan for Nicotine Dependence: Identification of a Chromosome 5 Risk Locus
  138. The serotonin transporter gene and stress reactivity in daily life
  139. Demographic changes and marker properties affect detection of human population differentiation
  140. Comorbid Psychiatric Diagnoses and Their Association with Cocaine-Induced Psychosis in Cocaine-Dependent Subjects
  141. Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans
  142. Human clock, PER1 and PER2 polymorphisms: lack of association with cocaine dependence susceptibility and cocaine-induced paranoia
  143. Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: A meta-analysis
  144. Diplotype Trend Regression Analysis of the ADH Gene Cluster and the ALDH2 Gene: Multiple Significant Associations with Alcohol Dependence
  145. Evidence-Based Treatments for Alcohol Dependence
  146. Genomewide Linkage Scan for Opioid Dependence and Related Traits
  147. Extended-Release Intramuscular Naltrexone
  148. Association study of theCNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence
  149. The effects of naltrexone on alcohol consumption and affect reactivity to daily interpersonal events among heavy drinkers.
  150. ADH4 gene variation is associated with alcohol and drug dependence: results from family controlled and population-structured association studies
  151. ADH4 Gene Variation is Associated with Alcohol Dependence and Drug Dependence in European Americans: Results from HWD Tests and Case–Control Association Studies
  152. The contribution of genetics to addiction therapy approaches
  153. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case–control structured association study
  154. Genomewide linkage scan for cocaine dependence and related traits: Significant linkages for a cocaine-related trait and cocaine-induced paranoia
  155. Does Effect Size in Naltrexone Trials for Alcohol Dependence Differ for Single-Site vs. Multi-Center Studies?
  156. Response to Dr. Kopke's comments on haplotypes at the OPRM1 locus
  157. Practical population group assignment with selected informative markers: Characteristics and properties of Bayesian clustering via STRUCTURE
  158. Meta‐analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence
  159. Incentive program decreases no-shows in nontreatment substance abuse research.
  160. Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis
  161. Drinking to cope: a comparison of questionnaire and electronic diary reports.
  162. A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence
  163. Allelic and haplotypic association of GABRA2 with alcohol dependence
  164. Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo‐Controlled Clinical Trial
  165. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment
  166. Association study of personality factors and the Asn40Asp polymorphism at the μ-opioid receptor gene (OPRM1)
  167. Typologies of drug dependence: comparative validity of a multivariate and four univariate models
  168. Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression
  169. CALCYON gene variation, schizophrenia, and cocaine dependence
  170. Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema
  171. Nogo 3′-untranslated region CAA insertion: failure to replicate association with schizophrenia and demonstration of marked population difference in frequency of the insertion
  172. Self-Efficacy as a Predictor of Relapse During Treatment for Alcohol Dependence
  173. Psychometric Properties of the Short Index of Problems as a Measure of Recent Alcohol‐Related Problems
  174. Measurement and Prediction of Medication Compliance in Problem Drinkers
  175. Barriers to the Use of Medications to Treat Alcoholism
  176. Effects of Ondansetron in Early‐ Versus Late‐Onset Alcoholics: A Prospective, Open‐Label Study
  177. Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers
  178. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European‐Americans
  179. Targeted Naltrexone for Early Problem Drinkers
  180. Salty and Sour Taste Characteristics and Risk of Alcoholism
  181. Salty and Sour Taste Characteristics and Risk of Alcoholism
  182. INTRODUCTION
  183. Dual Diagnosis: Alcoholism and Co‐Morbid Psychiatric Disorders
  184. Physicians’ opinions about medications to treat alcoholism
  185. Effect of Maternal Smoking on Fetal Catecholamine Concentrations at Birth
  186. Barriers to the Use of Medications to Treat Alcoholism
  187. Pharmacotherapies to enhance smoking cessation during pregnancy
  188. The Effect of Cigarette Smoking on Fetal Heart Rate Characteristics
  189. Screening for health behaviors in ambulatory clinical settings
  190. Association Study of Alcoholism Subtypes with a Functional Promoter Polymorphism in the Serotonin Transporter Protein Gene
  191. Genetic variation and drug dependence risk factors
  192. The Effect of Cigarette Smoking on Fetal Heart Rate Characteristics
  193. PMH44 SURVEY AND STATED PREFERENCE TECHNIQUES FOR ESTIMATING THE DEMAND FOR ALCOHOLISM MEDICATIONS
  194. Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism
  195. Ms. Sandstrom and Dr. Kranzler Reply
  196. Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of Alcohol
  197. The Status of Serotonin-Selective Pharmacotherapy in the Treatment of Alcohol Dependence
  198. Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
  199. Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis
  200. PMH32: BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM
  201. Reliability of personality disorder symptoms and personality traits in substance-dependent inpatients.
  202. Sweet Taste Preference as a Risk Factor for Alcohol Dependence
  203. Adverse effects of oral naltrexone: analysis of data from two clinical trials
  204. Double-Blind Clinical Trial of Sertraline Treatment for Alcohol Dependence
  205. Reliability of personality disorder symptoms and personality traits in substance-dependent inpatients.
  206. Medications for Alcohol Dependence—New Vistas
  207. Variant detection at the ? opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence
  208. Personality and substance use disorders as predictors of criminality
  209. Variant detection at the δ opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence
  210. Family-Based study of DRD2 alleles in alcohol and drug dependence
  211. Give them prizes and they will come: Contingency management for treatment of alcohol dependence.
  212. Factor replicability and validity of the Temperament and Character Inventory in substance-dependent patients.
  213. Rates of Personality Disorders in Substance Abusers: A Comparison Between DSM-III-R and DSM-IV
  214. Using cue reactivity to evaluate medications for treatment of cocaine dependence: a critical review
  215. PHARMACOLOGIC TREATMENTS FOR DRUG AND ALCOHOL DEPENDENCE
  216. No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans
  217. Validity of the Obsessive Compulsive Drinking Scale (OCDS)
  218. Factor replicability and validity of the Temperament and Character Inventory in substance-dependent patients.
  219. The validity of self-reported cocaine use in two groups of cocaine abusers.
  220. Validity of the Obsessive Compulsive Drinking Scale (OCDS): Does Craving Predict Drinking Behavior?
  221. Dr. Kranzler and Colleagues Reply
  222. PROP taster status and parental history of alcohol dependence
  223. Neuropsychologic findings in cocaine-dependent outpatients
  224. Variants in the ?2A AR adrenergic receptor gene in psychiatric patients
  225. Population Studies of Polymorphisms at Loci of Neuropsychiatric Interest (Tryptophan Hydroxylase (TPH), Dopamine Transporter Protein (SLC6A3), D3 Dopamine Receptor (DRD3), Apolipoprotein E (APOE), μ Opioid Receptor (OPRM1), and Ciliary Neurotrophic Fac...
  226. Association of Alcohol or Other Drug Dependence with Alleles of the mu Opioid Receptor Gene (OPRM1)
  227. Sustained-Release Naltrexone for Alcoholism Treatment
  228. Sustained‐Release Naltrexone for Alcoholism Treatment: A Preliminary Study
  229. Stage of Change as a Predictor of Abstinence among Alcohol‐Dependent Subjects in Pharmacotherapy Trials
  230. Treatment of Inhalant-Induced Psychotic Disorder With Carbamazepine Versus Haloperidol
  231. Personality Disorders in Substance Abusers: Relation to Substance Use
  232. Effects of naltrexone on cue-elicited craving for alcohol and cocaine
  233. Is the medication bottle half full or half empty?
  234. No allelic association of an exon 13 polymorphism of the Gsα gene to alcohol and/or drug dependence
  235. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal
  236. Targeted naltrexone treatment of early problem drinkers
  237. Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients
  238. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism.
  239. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers.
  240. Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive‐Behavioral Therapy in Type B Alcoholics
  241. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial
  242. Validity of the SCID in substance abuse patients
  243. Validity of the SCID in substance abuse patients
  244. No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence
  245. Elevated Rates of Early Discontinuation from Pharmacotherapy Trials in Alcoholics and Drug Abusers
  246. Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable
  247. Carbamazepine and cocaine-cue reactivity
  248. Handbook of experimental pharmacology, vol. 114: The pharmacology of alcohol abuse. Edited by Henry R. Kranzler. Springer-Verlag, Berlin, 1995. pp. 548. DM 498. ISBN 3-540-57125-6
  249. Validity of the Distinction Between “Substance‐Induced” and “Independent” Depression and Anxiety Disorders
  250. Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia
  251. The Pharmacology of Alcohol Abuse
  252. Validity of the Distinction Between “Substance-Induced” and “Independent” Depressio and Anxiety Disorders
  253. Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia
  254. Determination of fluvoxamine concentration in plasma by reversed‐phase liquid chromatography
  255. Personality disorders and associated features in cocaine-dependent inpatients
  256. Buspirone Treatment of Anxious Alcoholics
  257. Electroencephalographic activity and mood in cocaine-dependent outpatients: Effects of cocaine cue exposure
  258. Patient Predictors of Irregular Discharge From Inpatient Substance Abuse Treatment
  259. Naltrexone and Brief Counseling to Reduce Heavy Drinking
  260. Patient Predictors of Irregular Discharge from Inpatient Substance Abuse Treatment
  261. Naltrexone and Brief Counseling to Reduce Heavy Drinking:Results of a Small Clinical Trial
  262. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism.
  263. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism.
  264. Letter to the editor
  265. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism☆
  266. Cross system agreement for substance use disorders: DSM‐III‐R, DSM‐IV and ICD‐10
  267. Bromocriptine and cocaine cue reactivity in cocaine‐dependent patients
  268. Persistent Urinary Benzoylecgonine Following Cocaine Use
  269. Self‐reports by alcohol and drug abuse inpatients: factors affecting reliability and validity
  270. Alcohol and drug abuse treatment at the University of Connecticut Health Center
  271. Persistent Urinary Benzoylecgonine Following Cocaine Use
  272. Intragastric Infusion of Ethanol by Alcoholics After Surgery for Head and Neck Cancer
  273. Intragastric Infusion of Ethanol by Alcoholics After Surgery for Head and Neck Cancer
  274. Serum Prolactin Level, Craving, and Early Discharge from Treatment in Cocaine-Dependent Patients
  275. Headaches and Psychoactive Substance Use
  276. Substance Use Disorders in Patients With Chronic Fatigue
  277. The Identification and Treatment of Alcohol Abuse and Dependency
  278. Dental pathology and alcohol-related indicators in an outpatient clinic sample
  279. Giving ethanol to alcoholics in a research setting: its effect on compliance with disulfiram treatment
  280. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography
  281. Buspirone Treatment of Anxiety in a Patient Dependent on Alprazolam
  282. Early detection of harmful alcohol consumption: Comparison of clinical, laboratory, and self-report screening procedures
  283. Use of Buspirone in an Adolescent with Overanxious Disorder
  284. Anxiety and Depression in Substance Abuse: Clinical Implications
  285. Atypical Koro
  286. Phenothiazine-Associated Lupus Anticoagulant and Thrombotic Disease
  287. Psychosocial Issues Concerning a Pregnant Adolescent with Hodgkin's Disease
  288. Social Drinking as a Health and Psychosocial Risk Factor
  289. Current Perspectives in Cultural Psychiatry. E. F. Foulks, R. M. Wintrob, J. Westermeyer and A. R. Favazza, eds
  290. How to measure relapse in humans